Literature DB >> 3511383

Long-term pathological follow-up of cerebral arteriovenous malformations treated by embolization with bucrylate.

H V Vinters, M J Lundie, J C Kaufmann.   

Abstract

We examined 17 intracranial arteriovenous malformations that were resected after treatment by embolization using bucrylate (isobutyl-2-cyanoacrylate). In nine specimens removed 5 days to 16 months after embolization therapy, a series of pathologic changes was seen, including patchy mural angionecrosis (adjacent to bucrylate fragments) up to six weeks after embolization, the presence of bucrylate in vessel walls and fibromuscular intimal cushions, and the occurrence (after several months) of entirely extravascular bucrylate. Occasional parts of recanalized vascular malformations were identified. Bucrylate was present within arteriovenous malformations as late as 16 months after embolization, although the amount appeared to be diminished. These findings suggest a specific sequence of events in the interaction between bucrylate and mural components within the malformations and may explain some important complications of embolization therapy (e.g., delayed hemorrhage after embolization).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3511383     DOI: 10.1056/NEJM198602203140804

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  21 in total

1.  Use of a new mixture for embolization of intracranial vascular malformations. Preliminary experimental experience.

Authors:  P Lylyk; F Viñuela; H V Vinters; J Dion; J Bentson; G Duckwiler; T Lin
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

2.  Embolization of arteriovenous malformations prior to radiosurgery.

Authors:  S Miyachi; M Negoro; R Okamoto; G Otsuka; O Suzuki; J Yoshida
Journal:  Interv Neuroradiol       Date:  2001-05-15       Impact factor: 1.610

3.  Transvenous Treatment of a Dural Arteriovenous Fistula of the Transverse Sinus by Embolization with Platinum Coils and Onyx HD 500+.

Authors:  R Siekmann; W Weber; B Kis; D Kühne
Journal:  Interv Neuroradiol       Date:  2005-10-26       Impact factor: 1.610

4.  The use of Onyx for embolization of peripheral vascular malformations in pediatric patients.

Authors:  Murat Cantasdemir; Fatih Gulsen; Serdar Solak; Gokce Yalcin Gulsen; Fatih Kantarci; Furuzan Numan
Journal:  Pediatr Surg Int       Date:  2012-01-22       Impact factor: 1.827

5.  Revascularization of brain arteriovenous malformations after embolization with bucrylate.

Authors:  D Fournier; K Terbrugge; G Rodesch; P Lasjaunias
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

6.  Treatment of cerebral arteriovenous malformations by neuroradiological intervention and surgical resection.

Authors:  M Westphal; L Cristante; U Grzyska; N Freckmann; F Zanella; H Zeumer; H D Herrmann
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

Review 7.  Advances in Biomaterials and Technologies for Vascular Embolization.

Authors:  Jingjie Hu; Hassan Albadawi; Brian W Chong; Amy R Deipolyi; Rahul A Sheth; Ali Khademhosseini; Rahmi Oklu
Journal:  Adv Mater       Date:  2019-06-06       Impact factor: 30.849

8.  Temperature-sensitive poly(N-isopropylacrylamide-co-butyl methylacrylate) nanogel as an embolic agent: distribution, durability of vascular occlusion, and inflammatory reactions in the renal artery of rabbits.

Authors:  H Zhao; C Zheng; G Feng; Y Zhao; H Liang; H Wu; G Zhou; B Liang; Y Wang; X Xia
Journal:  AJNR Am J Neuroradiol       Date:  2012-08-02       Impact factor: 3.825

9.  Permanent inflammatory effect of N-butylcyanoacrylate on vascular wall immunohistochemical analysis.

Authors:  J Talan-Hranilović; T Rumboldt; M Vucic; Z Rumboldt; V Beros; V Tonković; V Lupret
Journal:  Interv Neuroradiol       Date:  2004-10-22       Impact factor: 1.610

Review 10.  Endovascular management of arteriovenous malformations of the brain.

Authors:  Charles A Bruno; Philip M Meyers
Journal:  Interv Neurol       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.